| Molecular Formula | C26H38N6O3 |
| Molar Mass | 482.62 |
| Density | 1.42±0.1 g/cm3(Predicted) |
| Solubility | H2O: soluble20mg/mL |
| pKa | 14.53±0.20(Predicted) |
| Storage Condition | Store at -20°C |
| In vitro study | RF9 (10 μM) pretrement completely blocks NPFF induced neurite outgrowth of Neuro 2A cells. |
| In vivo study | RF9 (0.1 mg/kg, s.c. ) with heroin coadministration prevents heroin-induced delayed hyperalgesia and tolerance. RF9 (10 μg) infused alone does not result in a significant alteration of MAP or heart rate. Conversely, MAP and heart rate increases evoked by NPFF are significantly blocked when NPFF is applied in conjunction with RF9. Animal Model: Rats. Dosage: 0.1 mg/kg. Administration: S.C. 30 min before 0.3 mg/kg heroin or saline on basal nociceptive threshold in rats. Result: Opposed to delaye heroin-induced hyperalgesia and associated tolerance. |
| WGK Germany | 3 |
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 1.676 ml | 8.38 ml | 16.76 ml |
| 5 mM | 0.335 ml | 1.676 ml | 3.352 ml |
| 10 mM | 0.168 ml | 0.838 ml | 1.676 ml |
| 5 mM | 0.034 ml | 0.168 ml | 0.335 ml |
| biological activity | RF9 is an effective and selective neuropeptide FF receptor (Neuropeptide FF receptor) antagonist, The Ki values for hNPFF1R and hNPFF2R are 58 and 7 nM respectively. |
| target | hNPFF1R 58 nM (Ki) hNPFF2R 75 nM (Ki) |
| in vitro study | RF9 (10 μM) pretrement completely blocks NPFF induced neurite outgrowth of Neuro 2A cells. |
| in vivo study | RF9 (0.1 mg/kg, S. c. ) with hero coadministration prevents hero-induced delayed hyperalgesia and tolerance. RF9 (10 μg) infused alone does not result in a significant alteration of MAP or heart rate. Conversely, MAP and heart rate increases evoked by NPFF are significantly blocked when NPFF is applied in conjunction with RF9. Animal Model: Rats. Dosage: 0.1 mg/kg. Administration: s.C. 30 min before 0.3 mg/kg nociceptive threshold in rat. Result: Opposed to delaye hero-induced hyperalgesia and associated tolerance. |
| Animal Model: | Rats. |
| Dosage: | 0.1 mg/kg. |
| Administration: | S.C. 30 min before 0.3 mg/kg heroin or saline on basal nociceptive threshold in rats. |
| Result: | Opposed to delaye heroin-induced hyperalgesia and associated tolerance. |